Beijing Luzhu Biotechnology Co., Ltd.
2480.HK
Hong Kong Stock Exchange12.75
HKD
- -
- -
ISIN
CNE100005YD8
Return %
Stock
S&P500
1Y
-48.80
25.65
3Y
-59.65
70.81
5Y
-42.05
77.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jian Kong
- Full Time Employees
- 193
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- No. 3 Guangtong Street Beijing BJ People's Republic of China
- IPO Date
- May 8, 2023
- Website
- luzhubiotech.com
- Similar Companies
- Business
- Beijing Luzhu Biotechnology Co., Ltd. engages in biopharmaceutical research, development, and commercialization focused on vaccines, biologics, and related therapeutic products. The company develops and manufactures recombinant vaccines and therapeutic antibodies intended to prevent, treat, and manage infectious diseases and autoimmune conditions, with a pipeline that includes recombinant zoster vaccines, monoclonal antibodies for autoimmune diseases, and bispecific antibody programs targeting hematologic malignancies. It also researches and develops recombinant vaccines for varicella, RSV, HSV (types 1 and 2), meningococcal and typhoid indications, and other conjugate vaccine platforms. The firm commercializes its products through partnerships and collaborations, aiming for domestic and international market presence. Headquarters are located in Beijing, China, and the company maintains corporate and operational activities in China with exploration of overseas licensing and distribution opportunities, including potential collaborations with global partners to accelerate global commercialization. Founded in 2001, Beijing Luzhu Biotechnology operates as a biotechnology company with subsidiary or affiliate structures to support research, development, manufacturing, and regional distribution. The main products and services are organized around vaccine development and production, therapeutic biologics development, clinical-stage and pre-clinical-stage candidates, and related research services, with ongoing activities to secure strategic alliances, fund-raising efforts, and potential acquisitions or reorganizations to support expansion. Its business model emphasizes partnerships with multinational pharmaceutical entities to leverage established sales networks for overseas commercialization, while pursuing国内市场的持续增长与扩展 to broaden market reach. The company’s geographic footprint centers on China with strategic attention to international collaborations to drive global access for its vaccine and biologics portfolio.